Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Elevated Levels of IgG2 Antibodies Protect Some Types of Gram-Negative Bacteria

By BiotechDaily International staff writers
Posted on 27 Aug 2014
Image: Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. They are found in the outer membrane of Gram-negative bacteria, and elicit strong immune responses in animals (Photo courtesy of Wikimedia Commons).
Image: Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. They are found in the outer membrane of Gram-negative bacteria, and elicit strong immune responses in animals (Photo courtesy of Wikimedia Commons).
The finding that an overabundance of a certain class of antibodies protects some bacteria from the effects of antibiotics has marked implications for our understanding of the protection generated by natural infections and for the design of vaccines, which should avoid inducing such inhibitory antibodies.

Investigators at the University of Birmingham (United Kingdom) worked with patients that had bronchiectasis—a chronic infection characterized by persistent cough, shortness of breath, and chest pain—or lung infection caused by the bacterium Pseudomonas aeruginosa.

They reported in the August 2014 online edition of the Journal of Experimental Medicine that in a significant portion of these patients, antibodies protected the bacterium from complement-mediated killing. Strains that resisted antibody-induced, complement-mediated killing produced a lipopolysaccharide containing O-antigen. In particular, they found that inhibition of antibody-mediated killing was caused by excess production of O-antigen–specific antibodies of the IgG2 class. Depletion of IgG2 to O-antigen restored the ability of sera to kill strains with long-chain O-antigen.

Patients with impaired serum-mediated killing of P. aeruginosa by IgG2 were shown to have poorer respiratory function than infected patients who did not produce the inhibitory antibody.

The authors suggested that excessive binding of IgG2 to O-antigen shielded the bacterium from other antibodies that could induce complement-mediated killing. Since there is significant sharing of O-antigen structure between different Gram-negative bacteria, this IgG2-mediated impairment of killing could be operating in other Gram-negative infections as well. These findings have marked implications for understanding the nature of protection generated by natural infections and for the design of vaccines, which should avoid inducing IgG2 class inhibitory antibodies.

Related Links:

University of Birmingham 



Channels

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.